Inify Laboratories enter into agreement with Swedish region
Inify Laboratories, a unique laboratory service that performs cancer diagnostics within pathology, has entered into an agreement with the region of Västmanland in Sweden on a pilot project with the goal of shortening waiting times for results to patients with suspected prostate cancer.
Pathology in large parts of the Western world is under enormous pressure, with an extensive mission and limited resources. One of the areas affected with long and varying lead times is prostate cancer diagnostics. Most regions in Sweden have challenges in reaching the goals that have been developed within the framework of the cancer patient pathways. These stipulate that the patient should receive the result within 11 days from the time of examination. For urology clinics, delayed pathology reports mean that administrative time is spent investigating when the results may be available and rescheduling patient visits.
The goal of the pilot project is to shorten waiting times for patients while making it easier for urologists to interpret the test results and plan treatment.
"The unique aspect of this initiative is not the use of effective digital tools and AI per se, but how the entire service, with high and consistent quality and more efficient processes, benefits both doctors and patients - from day 1," says Maria Holmberg, Sales and Marketing Manager at Inify Laboratories.
For more information, contact CEO Fredrik Palm, fredrik.palm@inify.com, or visit https://www.inify.com.
###
Inify Laboratories provides cancer diagnostics through ultramodern laboratory services within pathology. It uses a fully digital, standardized and AI- supported workflow to optimize quality and response times, initially within prostate. The concept is scalable and can be extended to other diagnoses. The service includes the whole chain of sample handling: from logistics, to sample preparation, to reporting by a pathologist. The report is assisted by our own AI, proven in clinical studies to have world-leading accuracy. The complete workflow is supported by a tailor-made process control system. The company, based in Sweden, became independent in 2022 through a spin-off from ContextVision, with 40 years of experience within digital imaging for medical applications. It is listed on Euronext Growth Oslo under the ticker INIFY.
Tags: